Background:
Reduced-dose direct oral anticoagulants (DOACs) are increasingly used after left atrial appendage closure (LAAC) in nonvalvular atrial fibrillation (NVAF), but their comparative efficacy and safety versus dual antiplatelet therapy (DAPT) remain uncertain, with no consensus on the optimal post-procedural...
A. Jha, N. Paudel, Mohammad Azeem Malik et al.· Circulation· 0 citations
Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agoni...
Ahmad Hassan, Qurrat Ul Ain Farooq, Fnu Parwesh et al.· F1000Research· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome describes the overlapping burden of metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Tirzepatide and semaglutide are both recommended for patients with type 2 diabetes and obesity, yet no randomized trial has directly compared their effect on...
A. Qadeer, M. Khalid, D. Leblanc et al.· Clinical Medicine Insights:...· 0 citations
Background Left atrial appendage occlusion (LAAO) offers a mechanical alternative to anticoagulation for stroke prevention in nonvalvular atrial fibrillation patients. However, the optimal anesthetic strategy—general anesthesia (GA) versus conscious sedation (CS)—during LAAO remains unclear. Methods A systematic sear...
Abubakar Nazir, Ahmad Hassan, Maaz Amir et al.· F1000Research· 0 citations
LCC- and HF-related mortality declined overall, with descriptive subgroup variation by sex, race/ethnicity, urbanization, and geography, and targeted screening, hepatitis management, and equitable healthcare access are needed to address these patterns.
S. Khan, Muneeb Khawar, Muhammad Haris Khan et al.· ASIDE Gastroenterology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.